Chen Yan, Li Xinli, Hou Dongni, Li Wenhao, Liu Zhike, Zhang Meng, Cheang IokFai, Shen Peng, Lin Hongbo, Zhan Siyan, Sun Feng, Song Yuanlin
Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People's Republic of China.
State Key Laboratory for Innovation and Transformation of Luobing Theory, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, People's Republic of China.
Int J Chron Obstruct Pulmon Dis. 2025 Jul 29;20:2659-2670. doi: 10.2147/COPD.S499783. eCollection 2025.
Triple therapy of chronic obstructive pulmonary disease (COPD), consisting of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) has shown benefits in patients with COPD. However, little is known about the use of triple therapy in Chinese patients. This study aims to describe the treatment patterns and the utilization of triple therapy in COPD patients based on real-world data from China.
This retrospective study included patients with COPD from the Yinzhou database. Patients aged ≥ 40 years with a diagnosis of COPD were included. Different combinations of ICS, LAMA and LABA prescribed during follow-up were categorized as single, dual, or triple therapies. Descriptive analysis was performed to depict the treatment patterns of each therapy.
A total of 7888 patients were prescribed at least one COPD therapy during the follow-up. Among them, 29.1% were prescribed triple therapy (ICS+LABA+LAMA) with a median (IQR) treatment duration of 3.27 (7.17) months. The majority (68.6%) of patients were prescribed dual therapy with ICS+LABA, while 27.3% and 23.3% of patients were prescribed single therapy with ICS or LAMA, respectively. Regarding treatment sequences during follow-up, 30.1% of patients received dual therapy with ICS+LABA, followed by 11.4% receiving only triple therapy and 10.4% receiving single therapy with ICS alone.
Our study assessed treatment patterns and triple therapy utilization among patients with COPD in China. The majority of patients were treated with ICS+LABA dual therapy. Triple therapy was also widely used, with most patients transitioning from other treatment modalities.
慢性阻塞性肺疾病（COPD）的三联疗法，即吸入性糖皮质激素（ICS）、长效β2受体激动剂（LABA）和长效毒蕈碱拮抗剂（LAMA）联合使用，已被证明对COPD患者有益。然而，三联疗法在中国患者中的使用情况鲜为人知。本研究旨在基于来自中国的真实世界数据，描述COPD患者的治疗模式和三联疗法的使用情况。
这项回顾性研究纳入了鄞州数据库中的COPD患者。纳入年龄≥40岁且诊断为COPD的患者。随访期间开具的ICS、LAMA和LABA的不同组合被分类为单药、双药或三联疗法。进行描述性分析以描绘每种疗法的治疗模式。
在随访期间，共有7888例患者至少接受了一种COPD治疗。其中，29.1%的患者接受了三联疗法（ICS+LABA+LAMA），中位（四分位间距）治疗持续时间为3.27（7.17）个月。大多数（68.6%）患者接受了ICS+LABA双药治疗，而分别有27.3%和23.3%的患者接受了ICS或LAMA单药治疗。关于随访期间的治疗顺序，30.1%的患者接受了ICS+LABA双药治疗，其次是11.4%的患者仅接受三联疗法，10.4%的患者仅接受ICS单药治疗。
我们的研究评估了中国COPD患者的治疗模式和三联疗法的使用情况。大多数患者接受了ICS+LABA双药治疗。三联疗法也被广泛使用，大多数患者是从其他治疗方式转换而来。
